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Abstract
Background: The current standard for induction phase treatment of lupus nephritis is steroid combined with
mycophenolate mofetil or pulse intravenous cyclophosphamide (IVC). The lowest dose of IVC recommended for
induction therapy is that used in the Euro-Lupus Trial. It is not known whether same cumulative dose of IVC would
be effective when given over six months.
Methods: We carried out a prospective, observational study on 41 patients of biopsy-proven lupus nephritis (class III,
IV, V or mixed). For induction, patients received six pulses of monthly IVC (500 mg each), along with steroid. Patients
were followed up monthly until one month beyond completion of the sixth pulse. The outcomes assessed were
complete remission (proteinuria < 200 mg/day or urine albumin nil with serum albumin >35 gm/L, stable estimated
glomerular filtration rate (eGFR) if normal at baseline or increase in eGFR by 25 % if abnormal at baseline and normal
urinary sediment), response (complete or partial remissions), complications of therapy and death.
Results: Twenty two patients (53.7 %) had class IV nephritis. Eighteen patients (43.9 %) achieved complete remission, 16
(39.0 %) achieved partial remission, yielding an overall response rate of 82.9 %. Nephrotic range proteinuria (UTP≥ 3 g/
day) and severe hypoalbuminemia (serum albumin < 20 g/L) at baseline influenced remission (p <0.05). Infection, seen in
12 patients (29.3 %), was the most common complication. Four deaths (9.6 %) were observed, all due to infection.
Conclusions: For induction phase treatment, Nepalese patients with lupus nephritis responded favorably to steroid and
low dose IVC of 3 grams given as six monthly pulses.
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Background
Approximately 35 to 50 % patients of systemic lupus er-
ythematosus (SLE) have clinically evident kidney disease
at presentation; during follow-up, lupus nephritis (LN)
develops in >60 % patients [1–4]. Overall survival in SLE
is 92 % at 10 years after diagnosis; presence of LN re-
duces survival to approximately 88 % at 10 years [2]. LN
affects the clinical outcomes both directly by target
organ damage and indirectly through complications of
therapy [1]. It is a major cause of end stage renal disease
(ESRD) and is associated with a greater than four-fold
increase in mortality [1, 5].
Use of the International Society of Nephrology/Renal
Pathology Society (ISN/RPS) 2003 classification can serve as
a guide to initial therapy of LN [2, 6, 7]. The management
of active class III, IV or V nephritis consists of an initial or
induction phase of aggressive immunosuppression followed
by a prolonged phase of less intense therapy [1, 2, 4, 7–9].
The current standard for the initial phase treatment consists
of steroid and intravenous cyclophosphamide (IVC) or my-
cophenolate mofetil (MMF) [1–4, 7, 9–20]. The NIH trials
used IVC at 0.5–1 g/m2 monthly for 6 months while the
Euro-Lupus Nephritis trial used IVC 500 mg every 2 weeks
for 3 months, lowering the dose and duration of IVC with-
out sacrificing the efficacy [11, 13].
In our center, lupus nephritis is routinely treated with
steroid and IVC at 500 mg monthly pulse for six months.
However, no systematic analysis of the outcome has been
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carried out so far. In this report, we present our experi-
ence with 41 Nepalese patients with lupus nephritis and
demonstrate that this dosing is clinically effective in our
population. We also analyzed the clinical and pathological
data, and related these findings to the outcome.
Methods
Design and settings
This study was a prospective, observational study con-
ducted at Tribhuvan University Teaching Hospital
(TUTH), Kathmandu, Nepal, between 14th April 2011
and 13th April 2013. Ethical approval was obtained from
the Institutional Review Board of Institute of Medicine.
Patients
A total of 41 consecutive patients with lupus nephritis
[2, 21] admitted to the nephrology wards of TUTH
during the study period were included. Patients were in-
cluded if they had a kidney biopsy [2, 21], were subse-
quently started on steroid and monthly pulse IVC for
induction treatment and gave informed consent for the
study. They were excluded if they did not give consent,
had previously received cyclophosphamide or if they
chose MMF as opposed to IVC for induction.
Clinical, biochemical and serological information was
obtained at baseline and at each return visit. Patients
were followed up monthly till one month beyond the
completion of the sixth pulse of IVC. For those patients
receiving IVC pulses in other hospitals, information was
recorded during TUTH visits later. For those patients
unable to attend our hospital later, information was re-
corded telephonically. The patients lost to follow up
were considered as non-responders in the outcome ana-
lysis. The decision to institute IVC pulses (rather than
MMF) in the initial phase of treatment was taken by the
treating nephrologists after discussion with the patients
and their relatives. Estimated glomerular filtration rate
(eGFR) was calculated using Cockroft-Gault formula at
baseline and at the final follow up visit [22].
Protocol
Criteria for performing kidney biopsies in SLE in TUTH
included increasing serum creatinine without alternative
causes, proteinuria ≥1.0 g/day, proteinuria ≥0.5 g/day
plus hematuria (≥5 RBCs/hpf ) or proteinuria ≥0.5 g/day
plus cellular casts. Renal biopsies were done in real time,
USG guided, with assistance of a radiologist, using a
Bard biopsy gun. Two cores of renal tissue were taken
and the sample was sent to Dr Lal PathLabs, a reference
laboratory in India.
Patients in the study received induction phase treatment
with steroid and pulse IVC, 500 mg monthly for six
pulses. Patients received total of 1000 ml intravenous fluid
during CYC infusion, duration of infusion being two
hours; none of the patients received mesna. The initial
steroid therapy consisted of intravenous methyl prednisol-
one pulses 500–1000 mg daily for three days, or oral
prednisolone 1 mg/kg/day; generally the patients with se-
vere pancytopenia, significant renal impairment, massive
proteinuria and active vasculitis were given intravenous
methyl prednisolone pulses if they did not have coexisting
infections. The dose of prednisolone was brought down to
0.5 mg/kg/day once the first pulse of IVC was given. Pa-
tients also received adjuvant therapy with hydroxychloro-
quine, calcium, proton pump inhibitor (PPI), angiotensin
converting enzyme inhibitor (ACEi) or angiotensin recep-
tor blocker (ARB) and prophylactic cotrimoxazole. The
dose of prednisolone was tapered gradually; there was no
fixed tapering protocol [4, 23, 24].
Complete blood counts were checked close to the 10th
day after the first pulse of IVC. Complete blood counts,
blood glucose, serum urea, serum creatinine, serum al-
bumin and urine routine and microscopy tests were
done every month prior to the next pulse IVC. Protein-
uria was quantified by 24 h urinary collection, at base
line and then at the completion of third and sixth pulses
of IVC. There was no fixed protocol for monitoring
serological lupus activity. After the initial phase of treat-
ment, patients were continued on steroid plus any of the
three: azathioprine, MMF or three monthly IVC.
Outcomes
Complete remission (CR) was defined as proteinuria of
less than 200 mg/day or urine albumin nil by dipstix
with serum albumin >35 g/L, stable eGFR if normal at
baseline or increase in eGFR by 25 % if abnormal at
baseline and normal urinary sediments (urinary RBC or
WBC <5/HPF each) [3, 25, 26].
Partial remission (PR) was defined as proteinuria be-
tween 200 mg to 2.9 g/day or fall in proteinuria by at
least 50 % with serum albumin at least 30 g/L and stable
eGFR if normal at baseline or increase in eGFR by 25 %
if abnormal at baseline [3, 25, 26]. Response was defined
as either CR or PR.
The adverse outcomes which were documented in-
cluded complications of therapy, ESRD or death.
Statistical analysis
For description of baseline characteristics mean ± stand-
ard deviation, median with range, frequency and per-
centages were used. ×2 test was used for categorical
variables and independent sample t test was used to
compare the means in different groups. The p value of
<0.05 was considered statistically significant. All statis-
tical analyses were performed using SPSS software
(version 16.0; SPSS Inc, http://www.ibm.com/analytics/
us/en/technology/spss/).
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Results
Patient characteristics
A total of 41 patients were enrolled in the study. Mean age
was 26.9 ± 10.6 years (range 14–61 years), female: male ra-
tio was 12.6:1 and the median duration of symptoms was
120 days (range, 4–5110 days). The main presenting symp-
toms were joint pain (in 70.7 %), limb swelling (in 65.8 %),
photosensitivity (in 41.7 %) and fever (in 39.0 %); other
symptoms were oliguria, malar rash, oral ulcer and hair
loss. Pallor and edema (each present in more than two-
thirds) and hypertension (in more than a third) were the
three most common examination findings at baseline.
All the patients were positive for antinuclear antibody
(ANA), while anti ds-DNA antibody was positive in
87.8 % of them. The majority, 56.1 % had eGFR < 60 ml/
min. Anemia, leukopenia and thrombocytopenia were
present in 73.2 %, 46.3 % and 26.8 % respectively. Simi-
larly, 87.8 % were hypoalbuminemic (serum albumin <
30 g/L), 41.5 % had severe hypoalbuminemia defined as
serum albumin < 20 g/L. Nephrotic range proteinuria
was present in 53.7 % patients, mean urinary total pro-
tein (UTP) being 3268 ± 2283 mg/day; 58.5 % had
microscopic hematuria. Hypothyroidism (clinical and
subclinical) was found in 29.3 % patients.
Renal biopsy findings
Twenty two patients (53.7 %) had ISN/RPS class IV
nephritis (Fig. 1). The mean activity index (AI) was 8.4 ±
4.8 and mean chronicity index (CI) was 3.5 ± 3.2; 16.2 %
had combined AI >7 & CI >3.
Relationship of baseline parameters with classes of lupus
nephritis
The patients with class IV LN had a shorter duration of
symptoms than other classes (p = 0.02); otherwise baseline
parameters did not differ significantly between different
classes of LN (Table 1). However, class IV patients tended
to have higher systolic blood pressure (SBP) and lower
platelet count compared to other classes (p > 0.05).
Management of patients
The median duration of hospitalization in the first epi-
sode was 9 days (range 2-41 days). All the patients re-
ceived six pulses of IVC, making a total of three grams.
Eighteen patients (43.9 %) received intravenous methyl
prednisolone (500 mg to 1000 mg) for three days. Fifteen
patients (36.6 %) received blood transfusion. All the pa-
tients received adjunctive hydroxychloroquine, cotri-
moxazole, calcium and oral PPI. A total of 34 patients
(82.9 %) were given ACEi or ARB therapy. The mean
dose of prednisolone at last follow up was 11.7 ± 4.2 mg/
day; 16 patients (42.1 %) were getting prednisolone
>10 mg/day while 10 patients (26.3 %) were still on
prednisolone ≥ 15 mg/day.
Outcome
A total of 18 patients (43.9 %) achieved complete remis-
sion, 16 (39.02 %) achieved partial remission; there were
four deaths and three were lost to follow up. All deaths
occurred before achieving remission. The response rate
(CR + PR) was 82.9 %. The mean time for urine albumin
to become negative in dipstix test was 163.6 ± 44.7 days.
Relationship of clinicopathological parameters with
response
Only nephrotic range proteinuria (urinary total protein,
UTP ≥ 3 g/day), severe hypoalbuminemia (serum albumin
< 20 g/L) and serum albumin significantly and negatively
affected attainment of remission (p < 0.05) (Table 2).
However, eGFR at presentation did not affect the attain-
ment of CR (p > 0.05). Those patients not entering remis-
sion were found to have longer duration of symptoms and
had higher blood pressure at presentation (p > 0.05). The
biopsy classes of LN and AI & CI did not influence the re-
mission rate. None of the four dialyzed patients achieved
CR (p > 0.05).
Adverse events
Infection was the most common adverse event noted in
12 patients (29.3 %) followed by hospital readmission
(19.5 %) (Fig. 2). Pneumonia was the most common infec-
tion complicating 10 out of 12 patients, one patient devel-
oped urinary tract infection (UTI) and the other one
developed herpes zoster. All the four deaths occurred in
class IV (p = 0.03) and all deaths were due to infection.
Acute kidney injury (AKI) resulted from hypovolemia sec-
ondary to excessive diuresis in one patient and severe UTI
leading to hypotension in the other. When all the adverse
events (dialysis, infection, leukopenia, readmission, AKI
and others) were combined, the difference between lupus



















ISN/RPS Classes of Lupus nephritis 
Fig. 1 International Society of Nephrology/Renal Pathology Society
(ISN/RPS) classes of lupus nephritis in renal biopsy (n = 41)
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Discussion
With the availability of effective treatment options to
control aggressive disease in lupus nephritis, the medical
community is seeking measures to decrease the toxicity of
therapy without compromising efficacy [1, 8, 9, 27]. An
ideal therapy for LN would be non-toxic, easy to adminis-
ter, affordable, would achieve early complete remission,
would not require prolonged use, would prevent relapse
and essentially cure the disease instead of controlling it.
Newer therapeutic options are being explored [5, 28, 29].
Our hospital uses a modified protocol of IVC, discussed
before, that is based on local experience, considers the rela-
tively smaller body surface area of our patients and aims to
decrease the gonadal toxicity of IVC in young females.
The demographic parameters, symptoms, signs and base-
line investigation findings of our cohort in general match
with that reported by other workers [3, 6, 25, 26, 30–36];
anemia was more common in our patients, and
hypothyroidism was seen in 12 patients (29.3 %). The base-
line eGFR and degree of proteinuria is comparable with the
renal findings in other studies, but the mean serum albu-
min was lower than that observed elsewhere [3, 25, 26, 31].
We had class IV nephritis in 53.7 % of our patients, that is
comparable with other studies [3, 25, 26, 36]. Our AI and
CI indices also match the findings of mean AI score 8.03 ±
5.12 and mean CI score of 2.84 ± 2.2.17 in a study by Yang
et al. [37]. These indices were higher than those reported
by Chen et al. [26].
In our study, class IV nephritis patients presented earlier
than other classes (p = 0.02) and tended to have higher sys-
tolic blood pressure and lower platelet count (p > 0.05);
otherwise there was no significant difference between class
IV and other classes on any of the other baseline parame-
ters. These findings support the ACR recommendation that
all patients with clinical LN, previously untreated, should
undergo renal biopsy (unless strongly contraindicated) [2].
Complete remission was achieved in 43.9 % patients in
our study; 39.0 % achieved partial remission, 9.6 % died and
7.3 % were lost to follow up. The response rate was 82.9 %.
Our response rate was higher than that observed in the
ALMS multicenter study, where the response rates were
56.2 % in the MMF group and 53.0 % in the IVC group [3].
In an NIH trial [11], the methylprednisolone and IVC
group attained a remission rate of 85 %; in a multicenter
Chinese study the CR and response rates to IVC as per
NIH protocol were 38.5 % and 82.1 % respectively [26];
these results were very similar to ours. In the Euro-Lupus
trial, renal remission was achieved in 71 % of the low-dose
group and 54 % of the high-dose group [13]. In the Ameri-
can study by Ginzler et al. [19], response rate to MMF was
52.1 % and in CYC was 30.4 %, rates far lower than what
we achieved. In the trial by Chan et al. in 42 Chinese pa-
tients, 81 % of the patients in MMF group achieved CR
compared with 76 % in the CYC; the response rates were
more than 90 % in each [17]. There is one important differ-
ence between our study and the other studies. Our patients
Table 1 Effects of baseline clinical and investigational parameters on classes of lupus nephrits
Parameter Class IV Other classes P value
(n = 22) (n = 19)
Mean age in years 26.2 (±8.7) 28.7 (±11.5) 0.42
Mean duration of symptoms in days 152.5 785.5 0.02
(±304.5) (±1206.2)
Number of patients with SBP (in mmHg)
≥140 9 (40.9 %) 5 (26.3 %) 0.33
<140 13 (59.1 %) 14 (73.7 %)
Mean leukocyte count/mm3 5702 5912 0.82
(±2345) (±3505)
Mean platelet count/mm3 145,395 206,805 0.09
(±66092) (±150947)
Mean hemoglobin in g% 9.2 (±2.3) 9.1 (±2.4) 0.88
Mean eGFR in ml/min 54.5 (±28) 62.9 (±42.4) 0.45
Number of patients with eGFR
≥60 ml/min 10 (45.4 %) 8(42.1 %) 0.83
<60 ml/min 12 (54.6 %) 11(57.9 %)
Mean serum albumin in g/L 21.5 (±5.6) 21.2 (±7.1) 0.88
Mean UTP in mg/day 3903.2 2533.1 0.05
(±2767.6) (±126.8)
SBP systolic blood pressure, eGFR estimated glomerular filtration rate, UTP urinary total protein, (±) standard deviation
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received a total of 3 grams IVC over six months, while the
other studies have used either IVC as per NIH protocol or
Euro lupus trial protocol with total of 3 grams of IVC in
three months) [11, 13]. The mean dose of prednisolone at
last follow up in our study was 11.7 ± 4.2 mg/day, compar-
able with the mean dose of prednisone on 24th week in the
Ginzler study [19]; however, we appreciate that this is still a
high dose which could potentially be associated with signifi-
cant side effects. These findings suggest that our induction
regime could be used in Nepalese lupus nephritis patients.
This IVC regime exposes the patients of LN to lower cu-
mulative dose of CYC given over longer duration so that
the side effects, especially infections and leukopenia will be
decreased without sacrificing efficacy.
Our study had good follow up; only three patients
(7.3 %) were lost to follow up. In the ALMS induction
trial, only 82.7 % patients remained in the study at 24th
week [3]. In the Ginzler’s study 17.14 % had to be with-
drawn from the study, though only 1.43 % were lost to
follow up [19].
Infection and leukopenia have always been major limit-
ing factor in lupus therapy. We had four deaths in our
study (9.8 %). All of them were class IV, had significant
anemia, hypoalbuminemia and markedly reduced eGFR;
they died early in the course due to infection complicating
severe disease. This corroborates the observation of other
workers that severe disease and infection are two import-
ant causes of early deaths in lupus [1, 8, 9]. Chan et al. also
Table 2 Relation of baseline parameters of patients with complete remission (CR) in lupus nephritis
Parameters CR (n = 18) No CR (n = 23) P value
Mean age in years 27.2 (±9.1) 27 (±11.3) 0.97
Mean duration of symptoms in days 438 (±541) 452(±1113) 0.96
Mean SBP in mmHG 124 (±20) 131(±22) 0.28
Mean DBP in mmHG 79 (±12.8) 83 (±12.1) 0.35
Mean eGFR in ml/min 54.5 (±33.9) 61.4 (±36.7) 0.54
Mean serum albumin in g/L 24.8 (±6.3) 18.6 (±4.8) 0.01
Number of patients with serum albumin
≥ 20 g/L 14 (77.8 %) 8 (34.8 %) 0.006
< 20 g/L 4 (22.2 %) 15 (65.2 %)
Number of patients with UTP (mg/day)
≥ 3000 6 (33.3 %) 16 (69.6 %) 0.02
< 3000 12 (66.7 %) 7 (30.4 %)
Number of patient with AI
>7 8 (50 %) 13 (61.9 %) 0.67
≤7 8 (50 %) 8 (38.1 %)
Number of patient with CI
> 3 4 (25 %) 8(38.1 %) 0.34
≤ 3 12 (75 %) 13 (61.9 %)
Number of patients with combined
AI >7 & CI >3 2 (12.5 %) 4 (19 %) 0.54
AI ≤7 & CI ≤ 3 14 (87.5 %) 17 (81 %)
Number of patients in different classes of LN
III 4 (80 %) 1 (20 %) 0.29
IV 9 (40.1 %) 13 (59.1 %)
V 1 (25 %) 3 (75 %)
III + V 1 (20 %) 4 (80 %)
IV + V 3 (60 %) 2 (40 %)
Number of patients
Dialyzed 0 4 (100 %) 0.06
Not dialyzed 18 (48.6 %) 19 (51.4 %)
SBP systolic blood pressure, DBP diastolic blood pressure, eGFR estimated glomerular filtration rate, UTP urinary total protein, AI activity index, CI chronicity index,
(±) standard deviation
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reported death rate of 10 %, similar to ours [17]. A lower
death rate of 3.78 %, was seen in the ALMS induction
study [3]; only three deaths out of 140 patients occurred in
Ginzler study [19]. This relatively higher death rate in our
study compared to those from the West could be because
of a relatively poorer support system and higher ambient
infection in Nepal. This was observed in the relatively
higher infection rates (29.3 %) without higher rates of
leukopenia in our patients. The ALMS study reported an
infection rate of 10 % in the IVC group and 12 % in the
MMF group [3]. Our infection rate is comparable with that
encountered by Chan et al. in their study over a decade
ago (19 % in MMF group and 33 % in the IVC group) [17].
Pneumonia was the most common infection observed by
us (in 10 out of 12 patients). We feel that balancing im-
munosuppression in aggressive disease against the risk of
potentially fatal infection is the art in the management of
lupus nephritis. Other adverse events observed in our
study were the need for dialysis (in 9.8 %), readmission (in
19.5 %) and leukopenia, AKI and others in 4.87 % each.
We did not observe gastrointestinal side effects, significant
alopecia or new onset menstrual irregularities; this is likely
because of the lower dose of IVC used.
Multiple factors are known to predict outcome in LN
[1, 8, 25, 38, 39]. We found that nephrotic range protein-
uria and hypoalbuminemia significantly affected the at-
tainment of remission (p < 0.05). Those patients who did
not enter remission had higher BP (p > 0.05) and none of
the dialyzed patients entered CR (p > 0.05); age and base-
line eGFR did not affect remission rates. These differences
could simply reflect the relatively small size of our study
population. We could not evaluate the influence of gender,
race, anti ds-DNA and complements in outcome. Ayodele
et al. showed class IV LN was histological predictor of
poor renal outcome [25]. We did not see difference in re-
mission rates when class IV was compared to other classes
(p = 0.29), however, class IV lupus negatively affected
survival in the short term (p = 0.03). We could not find
the significant influence of activity and chronicity indices
in outcomes (p > 0.05), unlike the findings of other
workers [6, 40]. When all the adverse outcomes were
combined, the difference between lupus class IV and other
classes was not significant (p = 0.25).
The limitations of the present study are that it was an
observational single center study with no control group.
There was no fixed tapering schedule for prednisolone,
some information during follow-up was collected tele-
phonically, and it was a short term study, without long-
term follow-up. There are, however, several strengths as
well. It is the first prospective study in patients with lupus
nephritis in Nepal, with a reasonable sample size and a
follow up rate of 92.7 %.
Conclusions
The response rate of 82.9 %, with complete remission in
43.9 %, suggests that the low-dose protocol used in the
study may be useful for initial phase treatment of lupus
nephritis without compromising efficacy. However, larger,
multicenter, multiethnic, randomised, controlled study is
required to provide stronger evidence.
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